EBD Group is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
ChinaBio Partnering Forum ChinaBio Group EBD Group ChinaBio Partnering Forum
Share/Follow Us
Share this:
Follow this event:

ChinaBio® Partnering Forum Program Overview

www.ebdgroup.com/cbpf/program
Tuesday, May 17, 2016
13:00–19:30
Hotel Lobby (2F)
Registration
13:30–14:00
Rooms K2 and K3 Foyer (1F)
Refreshments
14:00–17:30
Rooms K2 and K3 (1F)
Partnering Bootcamp: How to partner successfully in China
Sponsored by:
Cooley LLPCooley LLP
14:00–14:10
Welcome

Tuesday, 14:00–14:10

Speakers:
  • Greg B. Scott – Founder and Chairman, ChinaBio® Group
  • Christina Zhang, JD – Partner in Charge, Cooley LLP, Shanghai
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:10–15:10
Workshop
Doing cross-border JVs in China

Tuesday, 14:10–15:10

  • Benefits and dangers of JVs vs licensing
  • Onshore versus offshore and other key structuring decisions
  • Important terms and funding and exit strategies
  • Best practices and tips for building successful partnerships

Speakers:
  • Patrick Loofbourrow, JD – Partner, Cooley LLP, Shanghai
  • Christina Zhang, JD – Partner in Charge, Cooley LLP, Shanghai
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:10–15:30
Networking Break
15:30–16:30
Workshop
Negotiating term sheets for license and collaboration agreements

Tuesday, 15:30–16:30

  • Preliminary considerations
  • Dissection of key terms
  • Pitfalls and caveats

Speakers:
  • James Lu, JD – Partner, Cooley LLP, Shanghai
  • Bin Wang, PhD, JD – Senior Attorney, Cooley LLP, Shanghai
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:30–17:25
Panel Discussion
How to partner with a multinational pharma

Tuesday, 16:30–17:25

  • What multinational pharma are looking for in a partner
  • How to position your company or asset with an MNC
  • What to say in your first meeting with a potential partner
  • Follow-up: the key to success

Moderator:
Greg B. Scott – Founder and Chairman, ChinaBio® Group

Panelists:
  • Darren Ji, MD, PhD, MBA – VP, Global Head, Asia and Emerging Markets, Partnering, Roche
  • Connie Kim – Executive Director, Business Development, Hanmi Pharmaceutical
  • Nikie Shi, MBA – Director, Johnson & Johnson Innovation
  • Jonathan Wang, MBA – Executive Director and Head of Business Development, ZAI Lab
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:25–17:30
Closing Remarks
17:30–19:30
Garden Patio (1F), Kempinski Hotel, Suzhou
ChinaBio® Partnering Forum Welcome Reception

All ChinaBio® Partnering Forum attendees are cordially invited to join us for the Welcome Reception.

Garden Patio, Kempinski Hotel, Suzhou

Hosted by:
HanmiHanmi

You will be able to pick up your name badge at the Welcome Reception.

Wednesday, May 18, 2016
08:00–18:00
Hotel Lobby (2F)
Registration
08:00–09:00
Exhibit Area
Continental Breakfast
09:00–09:30
Welcome Remarks

Wednesday, 09:00–09:30
State Ballroom (2F)

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Greg B. Scott – Founder and Chairman, ChinaBio® Group
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:30–10:30
Keynote Panel
MNCs in China: Is the glass half full or half empty?

Wednesday, 09:30–10:30
State Ballroom

Headlines on China seem to warn of economic peril on a daily basis, while China's pharma industry, now the second largest market in the world, continues to grow at double-digit pace. Cross-border partnering and investment are at all time highs, with VC/PE investment reaching USD 6.3 billion in 2015, partnering deal value exceeding USD 4.2 billion, and M&A exploding to USD 16.5 billion. So are things in China as good—or as bad—as they sometimes appear? Learn the truth from MNC executives who are dealing with China's opportunities and challenges on a daily basis, and striking some of the largest cross-border transactions to date.

Moderator:
Greg B. Scott – Founder and Chairman, ChinaBio® Group

Panelists:
  • Darren Ji, MD, PhD, MBA – VP, Global Head, Asia and Emerging Markets, Partnering, Roche
  • Larry Lin, PhD, MBA – AVP, Head of Far East Innovation Hub, Business Development and Licensing, MSD
  • Ben Ni, PhD – AVP, Head of External Innovation and Partnering, Strategy and Business Development, Asia Pacific, Sanofi
  • Jeewoong Son, MD, PhD, MBA – Chief Medical Officer, Hanmi Pharmaceutical
  • Dong Wu, MBA – Head, Asia Pacific Innovation Center, Johnson & Johnson Innovation
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–11:00
Exhibit Area (2F)
Networking Break
10:30–17:00
One-to-one Meetings ►
10:30–18:00 Company Presentations ►
11:00–12:00
Plenary Panel
Innovation in China: Immuno-oncology

Wednesday, 11:00–12:00
Rooms K2 and K3 (1F)

The question used to be, is there innovation in China? That is no longer the case. China's leading drug development companies, many managed by returnees with significant global experience, are creating a strong pipeline of novel therapeutics targeting the global market. Government investment in the industry has reached over USD 100 billion annually, stimulating research and development of technologies such as CAR-T, PD-1/PD-L1, and other immuno-therapies to address unmet medical needs. This panel of executives from innovative I-O companies in China, the US and Europe will explore China's increasing contribution to the global race to create novel therapeutics.

Moderator:
Cyrus K. Mirsaidi – President and CEO, BioDuro

Panelists:
  • Samantha Du, PhD – Chairman and CEO, ZAI Lab
  • Henry Ji, PhD – President and CEO, Sorrento Therapeutics
  • Mike Liu, PhD, MBA – Head, Global Business Development, Hengrui Pharmaceuticals
  • Zhengying Zhu, MD, PhD – Deputy General Manager and Chief Medical Officer, Luoxin Pharmaceutical
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–13:30
Grand Ballroom (2F) and Rooms K7 and K8 (1F)
Luncheon
13:30–14:30
Panel Discussion
From theory to reality: How the right financial partner can pave the way to superior partnering opportunities

Wednesday, 13:30–14:30
Rooms K2 and K3 (1F)

This session will take you from how to evaluate prospective financial and strategic partners to developing and executing partnership arrangements with these partners. The founders of the successful investment firm, Ally Bridge Group, and their key advisors at the law firm Morrison & Foerster, will share insights on how ABG has spearheaded major cross-border transactions, including the USD 3.3 billion take-private of WuXi PharmaTech. Case studies will also be examined of how ABG's global partnership/portfolio network was able to deploy funds through a variety of investment structures (PE/VC, PIPEs, takeovers, hedge funds, etc.) and ultimately create accretive partnership opportunities and exits for both the portfolio companies and their strategic investors.

Moderator:
Thomas Chou, JD – Partner, Morrison & Foerster

Panelists:
  • Edward Hu, PhD, MBA – Chief Financial Officer and Chief Investment Officer, WuXi AppTec
  • Bin Li, PhD, MBA – Founder and Chief Investment Officer, Ally Bridge Group
  • Janet Xiao, PhD, JD – Partner, Morrison & Foerster
  • Frank Yu – Founder, CEO, and Chief Investment Officer, Ally Bridge Group
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:30–15:30
Panel Discussion
Cross-border innovation and investment in novel drug development in China

Wednesday, 14:30–15:30
Rooms K2 and K3 (1F)

With the recently announced positive regulatory and compliance policy reforms, novel drug development in China is set to boom. Besides domestic innovation, entrepreneurs in the field have also created cross-border business models, including investment in global clinical stage candidates and international collaborations for the best efficiency. On this panel, executives, advisors and investors will discuss their views on cross-border innovation and investment, and share their real-life experiences and lessons learned.

Moderator:
Dajun Yang, MD, PhD – Chairman and CEO, Ascentage Pharma Group

Panelists:
  • Li Chen, PhD – Co-Founder and CEO, Hua Medicine
  • Arthur Higgins – Senior Advisor, Blackstone Healthcare Partners
  • Sean Hu, PhD, MBA – Senior VP and Head of Consulting, GlobalData
  • Tina Yu, PhD, MBA – Managing Partner, YuanMing Capital
  • Jimmy Zhang, PhD, MBA – Former Chairman, Board of Directors, BayHelix Group
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–16:00
Exhibit Area (2F)
Networking Break
16:00–17:00
Panel Discussion
Rise of Chinese innovation and innovative deal structuring

Wednesday, 16:00–17:00
Rooms K2 and K3

China continues to be a hotbed for partnering activity, more than doubling in 2015 to over USD 4 billion in total announced deal value. Traditionally, Chinese partners tend to contribute heavily on infrastructure and other local resources performing a more “CRO-oriented” role. However, there has also been a rise in Chinese biotechs with truly innovative drug candidates that have attracted the attention of foreign pharmas. But doing partnering deals in China is not without challenge. This panel will explore the many aspects in partnering, from finding the right partners to deal negotiation and research collaboration. What are the issues and concerns that face both parties during a deal?

Moderator:
Lewis Ho, JD – Partner, Dechert LLP

Panelists:
  • Anand Gautam, PhD – Director, R&D Innovation Sourcing and Academic Partnerships, Novo Nordisk
  • Ruediger Hermann, PhD – Partner, Corporate Life Sciences, Dechert LLP
  • Xueming Qian, PhD – Chairman and CEO, MabSpace Biosciences
  • Cynthia Wang – Business Development Director, Servier
  • Brian Yang – Senior Writer/Editor, PharmAsia News
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:30–18:30
Bus tour of BioBAY Life Science Park

Take a brief tour of BioBAY, the fastest growing life science park in China, then go directly to the Gala Reception.

18:30–21:00
Gala Reception
The Noble Club

Crowne Plaza Suzhou
168 Xinggang Street
Suzhou Industrial Park
Suzhou, China

Hosted by:

Roche Roche

18:00–18:30: Shuttle buses directly from hotel to gala reception
21:00–21:30: Shuttle buses will transport guests from gala reception to hotel

Thursday, May 19, 2016
08:00–16:00
Hotel Lobby (2F)
Registration
08:00–09:00
Exhibit Area (2F)
Continental Breakfast
09:00–11:00
Pharma company presentations
Johnson & Johnson Innovation

Johnson & Johnson Innovation
Thursday, 09:00–09:15
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Hanmi Pharmaceutical

Hanmi Pharmaceutical
Thursday, 09:15–09:30
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:30–09:45
Roche

Roche
Thursday, 09:30–09:45
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:45–10:00
MSD

MSD
Thursday, 09:45–10:00
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:00–10:15
Sanofi

Sanofi
Thursday, 10:00–10:15
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:15–10:30
Bayer

Bayer
Thursday, 10:15–10:30
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–10:45
Novo Nordisk

Novo Nordisk
Thursday, 10:30–10:45
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–11:00
Servier

Servier
Thursday, 10:45–11:00
Rooms K5 and K6 (1F)

 

ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:00–16:00
One-to-one Meetings ►
09:30–10:30
Workshop
Overcoming critical legal and regulatory obstacles to inbound and outbound partnering and M&A transactions

Thursday, 09:30–10:30
Rooms K2 and K3 (1F)

Cross-border partnering and M&A transactions increasingly present attractive strategic and financial opportunities for Chinese and Western life science companies and investors. With respect to Chinese outbound transactions, this workshop will explore critical legal and regulatory challenges, and the various ways that strategic and financial players can prepare for and successfully overcome them. With respect to inbound transactions by Western companies, this workshop will discuss common pitfalls in China’s legal and regulatory environment, and how to navigate through them. Leaders of the workshop collectively have significant cross-border transaction experience and deep drug/device regulatory expertise, the combination of which is critical for highly complex cross-border life sciences transactions.

Speakers:
  • Shaoyu Chen, JD, LLB – Partner, Covington
  • Daniel B. Levine, JD – Special Counsel, Covington
  • Weishi Li, PhD, JD – Partner, Covington
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–11:00
Exhibit Area (2F)
Networking Break
11:00–12:00
Panel Discussion
Best time ever to raise venture capital in China?

Thursday, 11:00–12:00
Rooms K2 and K3 (1F)

In 2015, there were over USD 10 billion in new VC funds raised in China to invest in life science and healthcare, and there have already been over USD 6 billion raised this year. Many of these funds are investing in the West as well as in China. Due to the large supply of funding, and the competition for investment opportunities, VCs generally agree that now is the best opportunity to raise VC funding in China, in terms of both availability of funding and strong valuations. Hear from China's leading life science VCs what they are seeking, and how to best approach them to increase your chances of securing funding.

Moderator:
Greg B. Scott – Founder and Chairman, ChinaBio® Group

Panelists:
  • Francine Fang, PhD – Partner, 3E Bioventures
  • Jennifer Hu, MD, PhD – Partner, Qiming US Venture Fund
  • Tony Tong, PhD – VP, Decheng Capital
  • David Wang, MD, PhD – Senior Managing Director, OrbiMed Asia
  • Zhi Yang, PhD – Managing Partner and Founder, BVCF
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:00–16:00 Company Presentations ►
12:00–13:30
Grand Ballroom (2F) and Rooms K7 and K8 (1F)
Luncheon
13:30–15:30
Workshop
Meeting regulatory requirements for e-solutions in clinical trials in the US and China

Meeting regulatory requirements for e-solutions in clinical trials in the US and China
Thursday, 13:30–15:30
Rooms K2 and K3 (1F)

Experts in quality and regulatory affairs will discuss FDA regulatory requirements for information technology in clinical research in the US, and the future development of similar regulations in China. This session will also highlight how to effectively improve the quality of clinical data through the Medidata Clinical Cloud Platform, and ensure that the accuracy of the data will meet the new CFDA guidelines. Case studies will also be presented by Medidata users.

Speakers:
  • Zhiyang Chen, PhD – Director of Client Services, APAC, Medidata
  • Frances Nolan – VP of Quality and Regulatory Affairs, Medidata
ChinaBio® Partnering Forum 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–17:00
Exhibit Area (2F)
Closing Reception

All ChinaBio® Partnering Forum and Medidata session attendees are cordially invited to join us for the Closing Reception hosted by Medidata Solutions.

Hosted by:
MedidataMedidata

Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group
Privacy Policy and Cookies
Terms of Use